Notice from the Office of the Secretary - Ontario Securities Commission
KATANGA MINING LIMITED, ARISTOTELIS MISTAKIDIS, TIM HENDERSON, LIAM GALLAGHER, JEFFREY BEST, JOHNNY BLIZZARD, JACQUES LUBBE AND MATTHEW COLWILL, FILE NO. 2018-76
TORONTO, Dec. 17, 2018 /CNW/ - The Office of the Secretary issued a Notice of Hearing for a hearing to consider whether it is in the public interest to approve a settlement agreement entered into by Staff of the Commission and the respondentsin the above named matter.
The hearing will be held on December 18, 2018 at 9:00 a.m. on the 17th floor of the Commission's offices located at 20 Queen Street West, Toronto.
Apogee Enterprises, Inc. will report its fiscal 2024 fourth quarter and full-year results on Thursday, April 18, 2024, before the market opens. The company will also host a conference call to discuss its financial results. This conference call will...
Metals Acquisition Limited ARBN 671 963 198 , a private limited company incorporated under the laws of Jersey, Channel Islands ("MAC" or the "Company") announces its Annual Report for the financial year ended 31 December 2023 ("2023 Annual Report")....
Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual...
Verde AgriTech Ltd ("Verde" or the "Company") announces its financial results for the full year ended December 31, 2023 ("FY 2023") and the fourth quarter 2023 ("Q4 2023"), as audited by Ernst & Young ("EY"). The FY 2023 audited results were...
Hut 8 Corp. ("Hut 8" or the "Company"), a leading, vertically integrated operator of large-scale energy infrastructure and one of North America's largest Bitcoin miners, today announced its financial results for the six months ended...
Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value inflection points New Phase 3 GLOW2 study of tarcocimab in diabetic retinopathy actively...